

Equity Research - 5 November 2025 18:30 CET

Ascelia Pharma

Continuing to position itself for striking a deal

- An NDA for Orviglance submitted to the FDA
- Patience for a partner deal
- Fair value range updated: SEK 2.9-6.6 (2.6-6.9)

Preparing for a US approval and partner deal

Ascelia delivered a quarter largely in line with expectations, with operating CF at SEK -16m (SEK -18m in Q2) and cash and cash equivalents at SEK 72m (SEK 60m in Q2) after a directed share issue of net ~SEK 28m, and Fenja Capital's conversion of all outstanding convertibles of SEK 7.5m. Positively, opex decreased by ~35% and ~15% q-o-q and y-o-y, respectively. Following this, Ascelia expects a cash runway into Q4'26e, excluding potential partner revenues. Importantly, the *New Drug Application (NDA)* submission to the FDA for the MRI contrast agent Orviglance was submitted in early September. Ascelia expects a standard ten months review time, leading to an anticipated approval in July '26. This comes after the pivotal Ph 3 *SPARKLE* trial successfully met its primary endpoint, demonstrating that the company's MRI contrast agent Orviglance significantly ($p < 0.001$) improved the visualisation of metastatic liver lesions compared to un-enhanced MRI.

Estimate revisions

As before, we model that Orviglance will be commercialised through a partner - in line with sustained company guidance. We make the following estimate revisions to our model: i) A partner deal for Orviglance is delayed until '26e, which as before is accompanied by a USD 10m upfront payment; ii) A European launch is delayed from early '27e to late '27e, as this is planned to be undertaken by a partner; and iii) Commercial milestones are cut to USD 40m (USD 50m).

Valuation update

The changes listed above yield a new fair value range of SEK 2.9-6.6 (2.6-6.9), implying an attractive risk/reward. The strengthened balance sheet adds to this, particularly as it ensures sufficient funding through the key regulatory milestones and improves the company's negotiating position.

Analyst: georg.tigalonov-bjerke@abgsc.no, +47 22 01 60 84

SEKm	2024	2025e	2026e	2027e
Sales	0	0	150	75
EBITDA	-68	-75	79	8
EBITDA margin (%)	--	--	52.6	11.0
EBIT adj.	-68	-75	79	8
EBIT adj. margin (%)	--	--	52.6	11.0
Pretax profit	-80	-76	79	8
EPS	-0.83	-0.59	0.62	0.06
EPS adj.	-0.83	-0.59	0.62	0.06
Sales growth (%)	--	--	--	-50.0
EPS growth (%)	-74.3	-28.7	nm	-89.5

Source: ABG Sundal Collier, Company Data

Reason: Post-results comment

Commissioned research

Not rated

Healthcare

Estimate changes (%)

	2025e	2026e	2027e
Sales	-100.0	83.9	-24.6
EBIT	nm	nm	-70.0
EPS	nm	nm	-73.5

Source: ABG Sundal Collier

ACE-SE/ACE SS

Share price (SEK)	4/11/2025	3.06
Fair value range		2.9-6.6

MCap (SEKm)	388
MCap (EURm)	36
No. of shares (m)	126.8
Free float (%)	94.4

Next event Q4 Report 5 February 2026

Performance



	2026e	2027e
P/E (x)	5.0	47.3
P/E adj. (x)	5.0	47.3
P/BVPS (x)	2.20	2.10
EV/EBITDA (x)	3.3	30.2
EV/EBIT adj. (x)	3.3	30.2
EV/sales (x)	1.72	3.32
ROE adj. (%)	57.1	4.5
Dividend yield (%)	0.0	0.0
FCF yield (%)	20.2	2.1
Le. adj. FCF yld. (%)	20.2	2.1
Net IB debt/EBITDA (x)	-1.7	-17.1
Le. adj. ND/EBITDA (x)	-1.7	-17.3

Disclosures and analyst certifications are located on pages 7-8 of this report.

This research product is commissioned and paid for by the company covered in this report. As such, this report is deemed to constitute an acceptable minor non-monetary benefit (i.e. not investment research) as defined in MiFID II.


Company description

Ascelia Pharma is a Swedish biopharma company listed on the Nasdaq Stockholm main market since March 2019. The company is focused on the development of a novel non-gadolinium based MRI contrast agent for the detection of liver metastases in cancer patients with impaired kidney function. The product Orvigance has successfully completed clinical Ph 3 (SPARKLE) in 2024 and is now in final preparations towards submission of a NDA to the US FDA in early September. The second pipeline candidate Oncoral (novel chemotherapy formulation for gastric cancer) successfully completed Ph 1 and is Ph 2 ready.

Risks


Ascelia's lead drug candidate Orvigance has passed clinical development. Remaining risks remain FDA approval (small risk) and failure of meeting commercial targets (greater risk). Ascelia will also need to find a licensing partner to successfully launch the product and prolong the company's financial runway until sufficient revenue is generated from partner milestones and royalties to reach profitability.

Annual risk-adj. rev. (SEKm) and EBIT margin (%)




Source: ABG Sundal Collier, Company data

Risk-adj. Orvigance sales (SEKm)




Source: ABG Sundal Collier, Company data

Net operating CF and cash balance (SEKm)



Source: ABG Sundal Collier, Company data

Valuation range



Source: ABG Sundal Collier, Company data

Valuation summary

We model three different DCF scenarios:

In **scenario A**, we assume an Orviglance US list price of USD 1,500 and a worldwide royalty rate of 17.5%, yielding a DCF-fair value of **SEK 2.9/share**.

In **scenario B**, we assume an Orviglance US list price of USD 2,500 and a worldwide royalty rate of 20%, yielding a DCF-fair value of **SEK 4.3/share**.

In **scenario C**, we assume an Orviglance US list price of USD 3,500 and a worldwide royalty rate of 25%, yielding a DCF-fair value of **SEK 6.6/share**.

For all three scenarios, we use a weighted average cost of capital (**WACC**) of **12%** over the period '25e-'40e. As before, the vast majority of income over this period is modelled as derived from an out-licencing deal for Orviglance, while only a small portion of the revenue stream is derived from Oncoral sales, which still has a long path to market.

In total, this yields our fair value range of SEK 2.9-6.6 (2.6-6.9) per share for Ascelia Pharma.

Income Statement (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	0	0	0	0	0	0	0	150	75
COGS	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	150	75
Other operating items	-37	-93	-138	-147	-111	-68	-75	-71	-67
EBITDA	-37	-93	-138	-147	-111	-68	-75	79	8
Depreciation and amortisation	0	0	0	0	0	0	0	0	0
of which leasing depreciation	0	0	0	0	0	0	0	0	0
EBITA	-37	-93	-138	-147	-111	-68	-75	79	8
EO Items	0	0	0	0	0	0	0	0	0
Impairment and PPA amortisation	0	0	0	0	0	0	0	0	0
EBIT	-37	-93	-138	-147	-111	-68	-75	79	8
Net financial items	-3	-6	8	14	1	-12	-2	0	0
Pretax profit	-40	-100	-130	-133	-110	-80	-76	79	8
Tax	0	1	4	2	0	0	1	0	0
Net profit	-40	-99	-126	-131	-109	-80	-76	79	8
Minority interest	0	0	0	0	0	0	0	0	0
Net profit discontinued	0	0	0	0	0	0	0	0	0
Net profit to shareholders	-40	-99	-126	-131	-109	-80	-76	79	8
EPS	-1.70	-3.50	-3.74	-3.90	-3.24	-0.83	-0.59	0.62	0.06
EPS adj.	-1.70	-3.50	-3.74	-3.90	-3.24	-0.83	-0.59	0.62	0.06
Total extraordinary items after tax	0	0	0	0	0	0	0	0	0
Leasing payments	0	0	0	0	0	0	0	0	0
<i>Tax rate (%)</i>	<i>0.2</i>	<i>1.1</i>	<i>2.8</i>	<i>1.5</i>	<i>0.3</i>	<i>0.1</i>	<i>0.7</i>	<i>0.0</i>	<i>0.0</i>
<i>Gross margin (%)</i>	--	--	--	--	--	--	--	<i>100.0</i>	<i>100.0</i>
<i>EBITDA margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
<i>EBITA margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
<i>EBIT margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
<i>Pre-tax margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
<i>Net margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
Growth Rates y-o-y	-	-	-	-	-	-	-	-	-
<i>Sales growth (%)</i>	--	--	--	--	--	--	--	--	<i>-50.0</i>
<i>EBITDA growth (%)</i>	--	<i>153.7</i>	<i>47.7</i>	<i>6.6</i>	<i>-24.6</i>	<i>-38.9</i>	<i>10.2</i>	<i>-205.7</i>	<i>-89.5</i>
<i>EBITA growth (%)</i>	--	<i>153.7</i>	<i>47.7</i>	<i>6.6</i>	<i>-24.6</i>	<i>-38.9</i>	<i>10.2</i>	<i>-205.7</i>	<i>-89.5</i>
<i>EBIT growth (%)</i>	--	<i>nm</i>	<i>47.7</i>	<i>6.6</i>	<i>-24.6</i>	<i>-38.9</i>	<i>10.2</i>	<i>-205.7</i>	<i>-89.5</i>
<i>Net profit growth (%)</i>	--	<i>147.3</i>	<i>27.6</i>	<i>4.2</i>	<i>-16.7</i>	<i>-26.8</i>	<i>-5.1</i>	<i>-203.9</i>	<i>-89.5</i>
<i>EPS growth (%)</i>	--	<i>nm</i>	<i>6.8</i>	<i>4.2</i>	<i>-16.8</i>	<i>-74.3</i>	<i>-28.7</i>	<i>nm</i>	<i>-89.5</i>
Profitability	-	-	-	-	-	-	-	-	-
<i>ROE (%)</i>	<i>-33.7</i>	<i>-41.7</i>	<i>-46.3</i>	<i>-53.7</i>	<i>-85.7</i>	<i>-104.4</i>	<i>-85.4</i>	<i>57.1</i>	<i>4.5</i>
<i>ROE adj. (%)</i>	<i>-33.7</i>	<i>-41.7</i>	<i>-46.3</i>	<i>-53.7</i>	<i>-85.7</i>	<i>-104.4</i>	<i>-85.4</i>	<i>57.1</i>	<i>4.5</i>
<i>ROCE (%)</i>	<i>-29.8</i>	<i>-34.4</i>	<i>-46.6</i>	<i>-52.6</i>	<i>-83.5</i>	<i>-73.6</i>	<i>-69.8</i>	<i>56.7</i>	<i>4.5</i>
<i>ROCE adj. (%)</i>	<i>-29.8</i>	<i>-34.4</i>	<i>-46.6</i>	<i>-52.6</i>	<i>-83.5</i>	<i>-73.6</i>	<i>-69.8</i>	<i>56.7</i>	<i>4.5</i>
<i>ROIC (%)</i>	<i>-57.1</i>	<i>-101.6</i>	<i>-265.4</i>	<i>-363.6</i>	<i>-259.2</i>	<i>-163.8</i>	<i>-202.2</i>	<i>178.2</i>	<i>18.7</i>
<i>ROIC adj. (%)</i>	<i>-57.1</i>	<i>-101.6</i>	<i>-265.4</i>	<i>-363.6</i>	<i>-259.2</i>	<i>-163.8</i>	<i>-202.2</i>	<i>178.2</i>	<i>18.7</i>
Adj. earnings numbers	-	-	-	-	-	-	-	-	-
EBITDA adj.	-37	-93	-138	-147	-111	-68	-75	79	8
<i>EBITDA adj. margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
EBITDA lease adj.	-37	-93	-138	-147	-111	-68	-75	79	8
<i>EBITDA lease adj. margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
EBITA adj.	-37	-93	-138	-147	-111	-68	-75	79	8
<i>EBITA adj. margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
EBIT adj.	-37	-93	-138	-147	-111	-68	-75	79	8
<i>EBIT adj. margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>
Pretax profit Adj.	-40	-100	-130	-133	-110	-80	-76	79	8
Net profit Adj.	-40	-99	-126	-131	-109	-80	-76	79	8
Net profit to shareholders adj.	-40	-99	-126	-131	-109	-80	-76	79	8
<i>Net adj. margin (%)</i>	--	--	--	--	--	--	--	<i>52.6</i>	<i>11.0</i>

Source: ABG Sundal Collier, Company Data

Cash Flow (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	-37	-93	-138	-147	-111	-68	-75	79	8
Net financial items	-3	-6	8	14	1	-12	-2	0	0
Paid tax	0	-0	1	4	1	1	-0	0	0
Non-cash items	75	-63	7	-11	3	-8	25	0	0
Cash flow before change in WC	35	-163	-122	-140	-105	-86	-52	79	8
Change in working capital	-71	77	5	15	-21	24	-14	0	-0

Cash Flow (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Operating cash flow	-37	-86	-117	-125	-127	-63	-66	79	8
Capex tangible fixed assets	0	0	0	0	0	0	0	0	0
Capex intangible fixed assets	0	0	0	0	0	0	0	0	0
Acquisitions and Disposals	0	0	0	0	0	0	0	0	0
Free cash flow	-37	-86	-117	-125	-127	-63	-66	79	8
Dividend paid	0	0	0	0	0	0	0	0	0
Share issues and buybacks	0	93	187	0	-0	90	69	0	0
Leasing liability amortisation	-0	-1	-1	-1	-1	-1	-1	0	0
Other non-cash items	145	67	8	15	-1	3	2	0	0
Balance Sheet (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Goodwill	0	0	0	0	0	0	0	0	0
Other intangible assets	57	57	57	57	57	57	57	57	57
Tangible fixed assets	0	0	0	0	0	0	0	0	0
Right-of-use asset	0	2	2	0	1	0	1	1	1
Total other fixed assets	0	0	0	0	0	0	0	0	0
Fixed assets	57	59	59	58	58	57	58	58	58
Inventories	0	0	0	0	0	0	0	0	0
Receivables	1	3	6	5	2	6	3	3	3
Other current assets	83	9	7	7	5	3	3	3	3
Cash and liquid assets	109	185	262	150	22	75	56	134	143
Total assets	250	255	333	219	87	141	120	199	207
Shareholders equity	237	236	308	181	74	79	99	178	186
Minority	0	0	0	0	0	0	0	0	0
Total equity	237	236	308	181	74	79	99	178	186
Long-term debt	0	0	0	0	0	0	0	0	0
Pension debt	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0
Leasing liability	0	2	2	0	1	0	1	1	1
Total other long-term liabilities	0	0	0	0	0	0	0	0	0
Short-term debt	0	0	0	0	0	25	0	0	0
Accounts payable	5	4	6	16	2	5	7	7	7
Other current liabilities	8	14	18	21	10	32	13	13	13
Total liabilities and equity	250	255	333	219	87	141	120	199	207
Net IB debt	-108	-183	-260	-149	-21	-50	-55	-133	-142
Net IB debt excl. pension debt	-108	-183	-260	-149	-21	-50	-55	-133	-142
Net IB debt excl. leasing	-109	-185	-262	-150	-22	-50	-56	-134	-143
Capital employed	237	238	309	181	75	104	100	179	187
Capital invested	129	53	48	32	54	29	44	44	44
Working capital	71	-6	-11	-26	-5	-28	-14	-14	-14
EV breakdown	-	-	-	-	-	-	-	-	-
Market cap. diluted (m)	72	86	103	103	103	294	391	391	391
Net IB debt adj.	-108	-183	-260	-149	-21	-50	-55	-133	-142
Market value of minority	0	0	0	0	0	0	0	0	0
Reversal of shares and participations	0	0	0	0	0	0	0	0	0
Reversal of conv. debt assumed equity	-	-	-	-	-	-	-	-	-
EV	-36	-97	-157	-46	82	244	337	258	249
Total assets turnover (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	94.3	37.0
Working capital/sales (%)	--	--	--	--	--	--	--	-9.3	-18.6
Financial risk and debt service	-	-	-	-	-	-	-	-	-
Net debt/equity (%)	-45.7	-77.5	-84.4	-82.4	-28.0	-63.2	-55.2	-75.1	-76.2
Net debt / market cap (%)	-150.8	-212.2	-252.5	-144.8	-20.2	-17.0	-13.9	-34.1	-36.2
Equity ratio (%)	94.7	92.4	92.3	82.7	85.4	56.0	82.6	89.5	89.9
Net IB debt adj. / equity (%)	-45.7	-77.5	-84.4	-82.4	-28.0	-63.2	-55.2	-75.1	-76.2
Current ratio	14.90	11.19	11.44	4.32	2.48	1.35	3.09	7.06	7.48
EBITDA/net interest	11.6	14.8	16.4	10.6	84.9	5.5	42.3	--	--
Net IB debt/EBITDA (x)	2.9	2.0	1.9	1.0	0.2	0.7	0.7	-1.7	-17.1
Net IB debt/EBITDA lease adj. (x)	2.9	2.0	1.9	1.0	0.2	0.7	0.7	-1.7	-17.3
Interest coverage	7.5	4.5	63.3	32.6	44.3	4.7	13.8	--	--

Source: ABG Sundal Collier, Company Data

Share Data (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Actual shares outstanding	23	28	34	34	34	96	128	128	128
Actual shares outstanding (avg)	23	28	34	34	34	96	128	128	128

Share Data (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
All additional shares	0	0	0	0	0	0	0	0	0
Issue month	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assumed dil. of shares from conv.	0	0	0	0	0	0	0	0	0
As. dil. of shares from conv. (avg)	0	0	0	0	0	0	0	0	0
Conv. debt not assumed as equity	0	0	0	0	0	0	0	0	0
No. of warrants	0	0	0	0	0	0	0	0	0
Market value per warrant	0	0	0	0	0	0	0	0	0
Dilution from warrants	0	0	0	0	0	0	0	0	0
Issue factor	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Actual dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Reported earnings per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (SEKm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Shares outstanding adj.	23	28	34	34	34	96	128	128	128
Diluted shares adj.	23	28	34	34	34	96	128	128	128
EPS	-1.70	-3.50	-3.74	-3.90	-3.24	-0.83	-0.59	0.62	0.06
Dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
EPS adj.	-1.70	-3.50	-3.74	-3.90	-3.24	-0.83	-0.59	0.62	0.06
BVPS	10.09	8.37	9.14	5.37	2.21	0.82	0.77	1.39	1.45
BVPS adj.	7.66	6.35	7.45	3.68	0.51	0.23	0.33	0.94	1.01
Net IB debt/share	-4.61	-6.49	-7.72	-4.43	-0.62	-0.52	-0.43	-1.04	-1.11
Share price	3.06	3.06	3.06	3.06	3.06	3.06	3.06	3.06	3.06
Market cap. (m)	72	86	103	103	103	294	391	391	391
Valuation	-	-	-	-	-	-	-	-	-
P/E (x)	nm	nm	nm	nm	nm	nm	nm	5.0	47.3
EV/sales (x)	--	--	--	--	--	--	--	1.7	3.3
EV/EBITDA (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
EV/EBITA (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
EV/EBIT (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF yield (%)	-51.4	-99.2	-113.2	-121.7	-123.1	-21.4	-16.9	20.2	2.1
Le. adj. FCF yld. (%)	-51.5	-100.0	-114.1	-122.7	-123.9	-21.7	-17.1	20.2	2.1
P/BVPS (x)	0.30	0.37	0.33	0.57	1.39	3.72	3.96	2.20	2.10
P/BVPS adj. (x)	0.40	0.48	0.41	0.83	5.97	13.44	9.36	3.24	3.03
P/E adj. (x)	nm	nm	nm	nm	nm	nm	nm	5.0	47.3
EV/EBITDA adj. (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
EV/EBITA adj. (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
EV/EBIT adj. (x)	1.0	1.0	1.1	0.3	-0.7	-3.6	-4.5	3.3	30.2
EV/CE (x)	-0.2	-0.4	-0.5	-0.3	1.1	2.3	3.4	1.4	1.3
Investment ratios	-	-	-	-	-	-	-	-	-
Capex/sales (%)	--	--	--	--	--	--	--	0.0	0.0
Capex/depreciation	--	--	--	--	--	--	--	--	--
Capex tangibles / tangible fixed assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capex intangibles / definite intangibles	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation on intang / def. intang	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation on tangibles / tangibles	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Source: ABG Sundal Collier, Company Data

Analyst Certification

We, ABGSC Healthcare Research and Georg Tigelonov-Bjerke, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as "ABG Sundal Collier"), and the author(s) of this report, certify that notwithstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research ("independent research") or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

Analyst valuation methods

ABG Sundal Collier analysts may publish valuation ranges for stocks covered under Company Sponsored Research. These valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company's discounted cash flow (DCF). Another valuation method is the analysis of a company's return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g. the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Valuation ranges may be changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company's assets changes (in the cases of investment companies, property companies or insurance companies) or when factors impacting the required rate of return change.

Expected updates

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

Important Company Specific Disclosure

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, ABG Sundal Collier has no required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier, ownership in ABG Sundal Collier by the company(ies) to whom the report(s) refer(s) to, market making, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier has undertaken a contractual obligation to issue this report and receives predetermined compensation from the company covered in this report.

ABG Sundal Collier acted as Sole Global Coordinator and Bookrunner in connection with the SEK 30 million directed share issue in Ascelia Pharma

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of report: 11/5/2025 17:30.

All prices are as of market close on 4 November, 2025 unless otherwise noted.

Disclaimer

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/ have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained

from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., not its affiliates. Further information on the securities referred to herein may be obtained from ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website www.abgsc.com.

© Copyright 2025 ABG Sundal Collier ASA

Norway

Ruseløkkveien 26, 8th floor
0251 Oslo
Norway
Tel: +47 22 01 60 00
Fax: +47 22 01 60 60

Denmark

Forbindelsesvej 12,
2100 Copenhagen
Denmark
Tel: +45 35 46 61 00
Fax: +45 35 46 61 10

Sweden

Regeringsgatan 25, 8th floor
111 53 Stockholm
Sweden
Tel: +46 8 566 286 00
Fax: +46 8 566 286 01

United Kingdom

10 Paternoster Row, 5th floor
London EC4M 7EJ
UK
Tel: +44 20 7905 5600
Fax: +44 20 7905 5601

USA

140 Broadway, Suite 4604
New York, NY 10005
USA
Tel. +1 212 605 3800
Fax. +1 212 605 3801

Singapore

10 Collyer Quay
Ocean Financial Center
#40-07, Singapore 049315
Tel +65 6808 6082

Germany

Schillerstrasse 2, 5. OG
60313 Frankfurt
Germany
Tel +49 69 96 86 96 0
Fax +49 69 96 86 96 99

Switzerland

ABG Sundal Collier AG
Representative Office
Schwanenplatz 4
6004 Lucerne
Switzerland
Tel +41 79 502 33 39